Status:
UNKNOWN
Corifollitropin Alfa Application in PCOS Patients
Lead Sponsor:
Shin Kong Wu Ho-Su Memorial Hospital
Conditions:
In Vitro Fertilization
Eligibility:
FEMALE
20-38 years
Phase:
PHASE4
Brief Summary
Corifollitropin alfa, single dose administered sustains multiple follicular development for 7 days. However, It may induce ovarian hyperstimulation syndrome (OHSS), especially in high responder women ...
Detailed Description
BACKGROUNG: Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovulation induction. Therefore, Corifollitropin alfa, long acting recombinant follicular stimulation hormone (r...
Eligibility Criteria
Inclusion
- The diagnosis of PCOS was according Rotterdam criteria ( twoi of three) included:
- chronic anovulation manifested by the symptoms of oligomenorrhoea
- ultrasonographic evidence of polycystic enlarged ovary with over 10 peripherally located follicles of 3-8mm diameter around a dense central stroma
- hyperandrogenaemia (serum testosterone concentrations over 0.8 ng/ml) or clinical hyperandrogenism.
Exclusion
- A diagnosis of congenital adrenal hyperplasia, Cushing's syndrome, androgen-producing tumours, hyperprolactinaemia and thyroid dysfunction were all excluded.
- patients older than 38 years or with serum FSH level over 12 mIU/ml.
- patients wiht previous ovarian surgery
- husband with non-obstructive azoospermia
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02215135
Start Date
January 1 2014
Last Update
August 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Obstetrics and Gynecology, Shin-Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan